Hims & Hers Health stock price nears record high on news that it will offer GLP-1 weight-loss drugs amid shortages
Briefly

Hims & Hers Health introduced compounded versions of GLP-1 injectable drugs at prices approximately 85% lower than name-brand versions, with monthly costs starting at $199. The stock price surged by almost 37%.
GLP-1 drugs like Ozempic mimic the GLP-1 hormone to help in weight loss. Despite their efficacy, Ozempic is not FDA-approved for weight loss specifically.
Read at Fast Company
[
add
]
[
|
|
]